asxan.ai Agents Hub

Menopause Support

Evidence Stack

Hormone balance · vasomotor · bone density · sleep

Evidence-first menopause-wellness stack — what the human-evidence record actually shows for the ingredients most associated with vasomotor, bone-density, and sleep-anxiety support through perimenopause and beyond, including the honest nulls (black cohosh Cochrane "insufficient evidence"; vitamin D3 null fracture in the already-replete). This is mechanism and evidence mapping, not medical advice. Menopausal hormone therapy (MHT / HRT) decisions are a clinical conversation with your obstetrician-gynecologist or endocrinologist; nothing here substitutes for that conversation. All PubMed identifiers are verified against PubMed before inclusion; cross-market regulatory claims appear verbatim per their authorising authority (FDA · EFSA · ANVISA · TGA).

Last reviewed · How we assess evidence →

Quick Summary

  • Soy isoflavones have well-established meta-analytic signal for hot-flash reduction at ≥54 mg aglycone equivalents per day for ≥6 weeks. Taku 2012 (PMID 22433977) Menopause meta-analysis of 19 RCTs supported hot-flash frequency reduction at this dose / duration threshold. Effect size is modest but reproducible across trials. See /ingredients/soy-isoflavones/.
  • Soy isoflavones also have robust meta-analytic signal for postmenopausal BMD preservation. Barańska 2022 (PMID 36012916) J Clin Med meta-analysis of 18 RCTs reported BMD gains at the lumbar spine (1.63%, p = 0.0004), femoral neck (1.87%, p = 0.034), and total hip (0.39%, p = 0.013), with typical intervention ~106 mg/day over 6–24 months. The framing: modest but statistically meaningful BMD preservation in postmenopausal women.
  • Red clover (Trifolium pratense) isoflavones have moderate / mixed meta-analytic signal for hot-flash reduction — particularly in postmenopausal women with ≥5 daily hot flushes. Kanadys 2021 (PMID 33920485) Nutrients SR + meta-analysis reported a weighted mean difference of ~1.73 fewer hot flushes daily; effect most pronounced in postmenopausal women with ≥5 daily hot flushes, treated for 12 weeks with doses of ≥80 mg/day isoflavones, particularly when formulations contained higher proportions of biochanin A.
  • Black cohosh (Actaea racemosa) does NOT have meta-analytic support for menopausal symptoms. Leach 2012 Cochrane (PMID 22972105) systematic review of 16 RCTs (2,027 women) concluded "there is currently insufficient evidence to support the use of black cohosh for menopausal symptoms." No significant difference vs placebo for hot-flush frequency or menopausal symptom scores; hormone therapy was more effective than black cohosh. Honest framing: null / negative pooled signal.
  • Vitamin K2 (MK-7) supports postmenopausal BMD at 180 µg/day over 3 years. Knapen 2013 (PMID 23525894) Osteoporos Int 3-year RCT in postmenopausal women supported lumbar spine and femoral neck BMD. Mechanism: osteocalcin γ-carboxylation routes calcium into bone matrix. Critical safety: contraindicated on warfarin.
  • Vitamin D3 should be targeted to deficient postmenopausal women — NOT empirically supplemented in the already-replete. LeBoff 2022 VITAL (PMID 35939577) showed null fracture reduction in already-replete adults. Target the deficient (serum 25-OH-D < 20 ng/mL).
  • Magnesium has systematic-review-level support for anxiety / sleep / mood — relevant to menopausal sleep disturbance. Boyle 2017 (PMID 28445426) Nutrients systematic review supports magnesium for anxiety and sleep endpoints. Particularly relevant in the menopausal context where vasomotor symptoms, anxiety, and sleep disturbance interact.
  • This is not medical advice. Menopausal hormone therapy decisions require physician-led management. The stack below is mechanism and evidence mapping — discuss any menopause supplementation, and any MHT decision, with your obstetrician-gynecologist or endocrinologist.

The Evidence Stack

The "evidence" column below describes the strength and direction of the outcome evidence in qualitative terms — well-established, robust, moderate/mixed, preliminary/emerging, or null/negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

Ingredient Menopause / postmenopausal evidence (qualitative) Key Trial / Meta-analysis asxan.ai page
Soy Isoflavones Well-established for hot-flash reduction; robust for postmenopausal BMD preservation Taku 2012 PMID 22433977 (Menopause · meta of 19 RCTs · hot flash · ≥54 mg aglycone / ≥6 wk); Barańska 2022 PMID 36012916 (J Clin Med · meta of 18 RCTs · BMD lumbar 1.63% / femoral neck 1.87% / ~106 mg/d / 6–24 mo) /ingredients/soy-isoflavones/
Red Clover Moderate / mixed — hot-flash signal concentrated in the symptomatic-postmenopausal subgroup Kanadys 2021 PMID 33920485 (Nutrients SR + meta · ~1.73 fewer hot flushes/day · ≥80 mg/d · 12 wk · postmenopausal ≥5 daily flushes) /ingredients/red-clover/
Black Cohosh Null / negative — Cochrane "insufficient evidence" for menopausal symptoms Leach 2012 PMID 22972105 (Cochrane Database SR · 16 RCTs · 2,027 women · "insufficient evidence to support") /ingredients/black-cohosh/
Vitamin D3 Well-established in the deficient; null / negative in the already-replete (VITAL fracture) LeBoff 2022 VITAL PMID 35939577 (NEJM · 25,871 adults · vitamin D 2,000 IU/d · NULL fracture in replete · 5.3 y) /ingredients/vitamin-d3/
Vitamin K2 (MK-7) Robust for postmenopausal BMD (3-year RCT) Knapen 2013 PMID 23525894 (Osteoporos Int · 3-y RCT · 180 µg MK-7/d · lumbar + femoral BMD) /ingredients/vitamin-k2/
Magnesium Moderate / mixed — systematic-review anxiety / sleep signal (not vasomotor-specific) Boyle 2017 PMID 28445426 (Nutrients SR · magnesium / anxiety / sleep) /ingredients/magnesium/

How It Works

Each ingredient engages menopausal biology by a different route — soy and red clover isoflavones through SERM-like estrogen-receptor binding, MK-7 through osteocalcin γ-carboxylation and calcium routing, vitamin D3 through calcium absorption in the deficient, and magnesium through NMDA / GABA / HPA-axis modulation in the sleep-anxiety dimension.

Soy isoflavones — selective estrogen receptor modulator-like activity. Genistein and daidzein are isoflavone phytoestrogens with binding affinity for estrogen receptors, with relatively higher affinity for ERβ than ERα (a SERM-like profile). In postmenopausal women, declining endogenous estrogen drives vasomotor symptoms (hot flashes, night sweats) and accelerated bone resorption. Taku 2012 (PMID 22433977) Menopause meta-analysis of 19 RCTs supported hot-flash frequency reduction at ≥54 mg aglycone equivalents per day for ≥6 weeks. Barańska 2022 (PMID 36012916) J Clin Med meta-analysis of 18 RCTs supported BMD preservation at the lumbar spine (1.63% gain), femoral neck (1.87% gain), and total hip (0.39% gain) at typical doses ~106 mg/day over 6–24 months. The same mechanism plausibly underlies both endpoints. Equol-producer status (about 30–60% of populations vary in their gut microbial conversion of daidzein to S-equol) modulates individual response — equol producers may experience larger effects. See /ingredients/soy-isoflavones/.

Red clover (Trifolium pratense) — biochanin A, formononetin and the subgroup-specific signal. Red clover isoflavones include biochanin A (a methylated genistein precursor) and formononetin (a methylated daidzein precursor). Kanadys 2021 (PMID 33920485) Nutrients SR + meta-analysis reported a weighted mean difference of ~1.73 fewer hot flushes daily for red clover vs placebo. The strongest signal emerged in subgroups: postmenopausal women experiencing ≥5 daily hot flushes, treated for 12 weeks with ≥80 mg/day isoflavones, particularly when formulations contained higher proportions of biochanin A. The authors framed the finding as a "statistically moderate relationship" — modest but reproducible in the symptomatic-postmenopausal subgroup.

Black cohosh (Actaea racemosa) — Cochrane insufficient evidence. Black cohosh (formerly Cimicifuga racemosa) rhizome extracts have been used for menopausal symptoms; the mechanism has been variously hypothesized as serotonergic (5-HT1A / 5-HT7), dopaminergic, GABAergic, or non-estrogenic CNS modulation — but none have been definitively demonstrated to underlie clinical signals. Leach 2012 Cochrane (PMID 22972105) systematic review of 16 RCTs (2,027 women) concluded "there is currently insufficient evidence to support the use of black cohosh for menopausal symptoms" — no significant difference vs placebo for hot-flush frequency or menopausal symptom scores; hormone therapy was more effective than black cohosh. The honest reading: black cohosh carries a null / negative pooled signal for menopausal symptoms.

Vitamin D3 — baseline-status-driven and the postmenopausal context. Postmenopausal women are at elevated risk for vitamin D deficiency given indoor-skewed lifestyle and altered skin synthesis with aging. LeBoff 2022 VITAL fracture sub-study (PMID 35939577) in 25,871 adults reported vitamin D3 2,000 IU/day produced NULL fracture reduction in already-replete adults over a median 5.3 years; Kong 2022 (PMID 35504603) meta-analysis, by contrast, supports D + Ca fracture reduction in deficient populations. The right framework: serum 25-OH-D testing is the cleanest entry point; target the deficient, NOT empiric supplementation of replete postmenopausal women.

Vitamin K2 (MK-7) — osteocalcin γ-carboxylation and the calcium-routing story. MK-7 is the cofactor for γ-glutamyl carboxylase, which γ-carboxylates osteocalcin (bone-Gla protein); carboxylated osteocalcin binds calcium hydroxyapatite in bone matrix. Knapen 2013 (PMID 23525894) Osteoporos Int 3-year RCT in postmenopausal women supported lumbar spine and femoral neck BMD at 180 µg MK-7 per day. The mechanism complements (does not replace) D3 + calcium. Critical safety: contraindicated for anyone on warfarin or other vitamin-K-antagonist anticoagulants.

Magnesium and the menopausal-sleep / anxiety dimension. Magnesium is a cofactor in >300 enzymatic reactions and modulates NMDA receptor activity, GABA signaling, and HPA-axis tone. Boyle 2017 (PMID 28445426) Nutrients systematic review supports magnesium for anxiety, sleep, and mood endpoints. In the menopausal context, vasomotor symptoms (especially night sweats), anxiety, and sleep disturbance interact — magnesium is layered as a sleep / anxiety adjunct rather than a vasomotor-specific intervention. Glycinate and citrate forms are typically preferred for GI tolerance.

Body systems engaged: Endocrine & Metabolic · Reproductive · Musculoskeletal. Mechanism tags: Estrogen receptor binding affinity · Mineral metabolism · Free radical scavenging.

What the Trials Show — Including the Nulls

Black cohosh has Cochrane-pooled INSUFFICIENT evidence — and isolated hepatotoxicity case reports. Leach 2012 Cochrane (PMID 22972105) found no significant difference vs placebo for hot-flush frequency or menopausal symptom scores across 16 RCTs in 2,027 women. Additionally, regulatory authorities (UK MHRA, EU EMA, Australia TGA) have flagged rare hepatotoxicity case reports associated with black cohosh products. The combination of weak efficacy evidence and rare-but-serious adverse event signals does NOT support routine recommendation.

Vitamin D3 in already-replete postmenopausal adults does NOT reduce fractures. LeBoff 2022 VITAL (PMID 35939577) — 25,871 generally healthy adults supplemented with vitamin D3 2,000 IU/day for a median 5.3 years showed NO reduction in total, non-vertebral, or hip fractures. Kong 2022 (PMID 35504603) meta-analysis, by contrast, supports D + Ca fracture reduction in deficient populations. Target the deficient. Do NOT empirically supplement the replete.

Red clover signal is subgroup-specific — the broader unselected meta-analytic effect is modest. Kanadys 2021 (PMID 33920485) anchored the strongest signal in postmenopausal women with ≥5 daily hot flushes treated for 12 weeks at ≥80 mg/day. In unselected, less-symptomatic, or shorter-duration cohorts, the effect attenuates. Equol-producer status may also matter (as for soy).

Soy isoflavones are contraindicated or require caution in women with hormone-sensitive cancer history. Women with a history of estrogen-receptor-positive breast cancer should NOT use soy isoflavone supplements without explicit oncologist guidance — the SERM-like mechanism is theoretically relevant. Dietary soy intake (tofu, edamame, soy milk in moderate amounts) appears safe in observational survivor cohorts, but supplement-dose isoflavones differ qualitatively from food-form soy intake.

Vitamin K2 (MK-7) is contraindicated for anyone on warfarin or other vitamin-K-antagonist anticoagulants. MK-7 directly antagonizes warfarin's mechanism. Talk to your prescriber.

Foundational lifestyle levers carry the largest effect sizes. Sleep, regular structured exercise (including weight-bearing and resistance training), Mediterranean-pattern diet, body-composition management, and stress modulation have the largest effect sizes on menopausal quality-of-life. Supplements are layered context; they do NOT substitute for these foundational interventions.

Stacking & Timeline

Mechanistic pairings are plausible but rarely backed by head-to-head synergy trials; realistic timelines run from weeks (hot-flash reduction) to years (bone-density preservation) — and lifetime for cumulative fracture-risk modification.

Mechanistic pairs

Soy Isoflavones · the dual-endpoint anchor. Taku 2012 (PMID 22433977) hot-flash signal + Barańska 2022 (PMID 36012916) BMD signal anchored to the same mechanism (SERM-like ERβ-preferential binding). One ingredient covering two endpoints is unusual in the supplement literature — soy isoflavones are the closest thing to an "anchor" ingredient in evidence-anchored menopause supplementation.

Soy Isoflavones + Red Clover · the isoflavone-class layered approach. Both anchor hot-flash reduction via phytoestrogen mechanism. Direct head-to-head comparison RCTs are limited; the practical question is whether layering provides additive benefit over either alone — current evidence does NOT specifically answer this. Single-source isoflavone at trial-validated dose / duration is the cleaner starting point.

MK-7 + Vitamin D3 (if deficient) + Calcium · the postmenopausal bone-mineralization triad. Knapen 2013 (PMID 23525894) MK-7 BMD signal + targeted D3 + dietary calcium = mechanism-non-redundant bone-preservation stack. Honest caveat: in already-replete adults the marginal benefit of additional D3 is null (LeBoff 2022 VITAL PMID 35939577). See /ingredients/vitamin-d3/ for the D3-specific evidence base.

Magnesium + Sleep Hygiene · the night-sweat / anxiety dimension. Boyle 2017 (PMID 28445426) magnesium anxiety / sleep signal layers with foundational sleep-hygiene interventions (consistent schedule, cool bedroom, evening light reduction, caffeine cutoff) for the menopausal sleep-disturbance dimension. NOT a vasomotor-specific intervention.

When to see results — realistic timeframes

6 weeks · soy isoflavone hot-flash window. Taku 2012 (PMID 22433977) — ≥54 mg aglycone equivalents per day for ≥6 weeks is the dose / duration threshold for measurable hot-flash frequency reduction.

12 weeks · red clover hot-flash window (in ≥5-daily-flush postmenopausal subgroup). Kanadys 2021 (PMID 33920485) — strongest signal at 12 weeks at ≥80 mg/day isoflavones in postmenopausal women experiencing ≥5 daily hot flushes.

6–24 months · soy isoflavone BMD window. Barańska 2022 (PMID 36012916) — pooled BMD effects emerged predominantly at 6–24 month intervention durations at ~106 mg/day. BMD is slow-changing; short-term assessment is uninformative.

3 years · MK-7 BMD preservation window. Knapen 2013 (PMID 23525894) is a 3-year RCT. Bone density preservation is a multi-year intervention.

Lifetime · cumulative bone-density preservation through perimenopause and beyond. Postmenopausal bone loss is most rapid in the first 5–10 years after the final menstrual period. Sustained intervention (lifestyle + targeted supplementation ± MHT decision) across this window meaningfully alters lifetime fracture risk. Short-term supplementation does not.

Frequently Asked Questions

1. Can soy isoflavones replace menopausal hormone therapy?

No — and that framing misses the point. For severe vasomotor symptoms, MHT (systemic estrogen ± progestin, or transdermal regimens) is the most effective intervention. Soy isoflavones at trial-validated doses (≥54 mg aglycone equivalents per day for ≥6 weeks per Taku 2012 PMID 22433977) produce a modest but reproducible hot-flash frequency reduction — meaningful for mild-moderate symptoms or for women who prefer non-hormonal approaches, but NOT equivalent to MHT efficacy. Discuss MHT decisions with your obstetrician-gynecologist or endocrinologist.

2. Are soy isoflavones safe if I have a history of breast cancer?

This requires explicit oncologist guidance. Women with a history of estrogen-receptor-positive breast cancer should NOT use soy isoflavone supplements without consulting their oncologist — the SERM-like mechanism is theoretically relevant. Observational data on dietary soy intake (tofu, edamame, soy milk in moderate amounts) in breast cancer survivor cohorts have not shown harm, but supplement-dose isoflavones differ qualitatively from food-form soy. The cleaner default for hormone-sensitive cancer survivors is to avoid supplement-dose isoflavones until directed otherwise.

3. Does black cohosh actually work for hot flashes?

Per Leach 2012 Cochrane (PMID 22972105) systematic review of 16 RCTs in 2,027 women — no. The Cochrane authors concluded "there is currently insufficient evidence to support the use of black cohosh for menopausal symptoms"; no significant difference vs placebo for hot-flush frequency or menopausal symptom scores. Additionally, regulatory authorities have flagged rare hepatotoxicity case reports. The combination of weak efficacy evidence and rare-but-serious adverse event signals does not support routine recommendation.

4. Does red clover work as well as soy isoflavones?

Both anchor hot-flash reduction via phytoestrogen mechanism, but the trial bodies differ. Kanadys 2021 (PMID 33920485) red clover meta found the strongest signal in a specific subgroup — postmenopausal women experiencing ≥5 daily hot flushes treated for 12 weeks at ≥80 mg/day isoflavones, particularly higher-biochanin-A formulations. Taku 2012 (PMID 22433977) soy meta supported ≥54 mg aglycone equivalents per day for ≥6 weeks. The effect sizes are broadly similar in magnitude (modest). Direct head-to-head comparison RCTs are limited.

5. Should every postmenopausal woman take vitamin D?

No — target the deficient. LeBoff 2022 VITAL fracture sub-study (PMID 35939577) in 25,871 already-vitamin-D-replete generally healthy adults reported vitamin D3 2,000 IU/day for a median 5.3 years produced NO reduction in fractures. Kong 2022 (PMID 35504603) meta-analysis supports D + Ca fracture reduction in deficient populations. Serum 25-OH-D testing is the cleanest entry point; supplement to address documented deficiency rather than empirically supplement the already-replete.

6. Can magnesium help with menopausal sleep problems?

Boyle 2017 (PMID 28445426) Nutrients systematic review supports magnesium for anxiety and sleep endpoints. In the menopausal context, vasomotor symptoms (especially night sweats), anxiety, and sleep disturbance interact — magnesium is a reasonable adjunct on top of sleep hygiene (consistent schedule, cool bedroom, evening light reduction, caffeine cutoff). It is NOT a vasomotor-specific intervention and does not directly address hot flashes. Glycinate or citrate forms are typically preferred for GI tolerance.

7. Why does this page list black cohosh if the evidence is insufficient?

Honest-negative context. Black cohosh is one of the most-promoted menopause botanicals, so the responsible thing is to state plainly what the pooled evidence shows rather than omit it. Leach 2012 Cochrane (PMID 22972105) found insufficient evidence to support it for menopausal symptoms, and there are rare hepatotoxicity case reports. Including it as a null / negative entry is more useful than silently leaving it off — it lets you weigh it against the well-established and robust options (soy isoflavones, MK-7) on the same page.

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

Citation corrections. An earlier version of this page cited PMID 22972104 for the Leach 2012 black cohosh Cochrane review, which actually indexes a different Leach paper on cinnamon for diabetes; the correct citation is PMID 22972105.

  1. PMID 22433977 · Taku K et al. (2012) · Menopause · soy isoflavone hot-flash meta of 19 RCTs · frequency reduction at ≥54 mg aglycone equivalents/day for ≥6 weeks
  2. PMID 36012916 · Barańska A et al. (2022) · J Clin Med · soy isoflavone BMD meta of 18 RCTs · lumbar spine 1.63% / femoral neck 1.87% / total hip 0.39% · ~106 mg/day · 6–24 months
  3. PMID 33920485 · Kanadys W et al. (2021) · Nutrients · red clover hot-flash SR + meta · ~1.73 fewer hot flushes/day · ≥80 mg/day · 12 weeks · postmenopausal ≥5 daily flush subgroup
  4. PMID 22972105 · Leach MJ, Moore V (2012) · Cochrane Database Syst Rev · black cohosh · 16 RCTs · 2,027 women · "insufficient evidence to support" for menopausal symptoms
  5. PMID 23525894 · Knapen MHJ et al. (2013) · Osteoporos Int · MK-7 180 µg/day 3-year RCT in postmenopausal women · lumbar spine + femoral neck BMD supported
  6. PMID 35939577 · LeBoff MS et al. (2022) · VITAL fracture sub-study · NEJM · vitamin D3 2,000 IU/day · NULL fracture reduction in already-replete adults · 5.3 y
  7. PMID 35504603 · Kong SH et al. (2022) · vitamin D + calcium fracture meta-analysis · fracture reduction in deficient populations (cross-reference context)
  8. PMID 28445426 · Boyle NB et al. (2017) · Nutrients · magnesium and subjective anxiety / stress / sleep systematic review

Coverage Notes

This Menopause Support page draws from six linked ingredient pages on asxan.ai (soy isoflavones, red clover, black cohosh, vitamin D3, vitamin K2 (MK-7), magnesium); their menopause-relevant evidence is described qualitatively here (well-established → null/negative) from the meta-analyses and RCTs cited above. Citations on this page are verified against PubMed; this page cites PMID 22972105 for the Leach 2012 black cohosh Cochrane review. Regulatory note: rare hepatotoxicity case reports associated with black cohosh have been flagged by UK MHRA, EU EMA, and Australia TGA; MK-7 is contraindicated on warfarin and other vitamin-K-antagonist anticoagulants. Educational reference only — not medical advice. Menopausal hormone therapy decisions are a clinical conversation with your obstetrician-gynecologist or endocrinologist.

← Home

Ask Agent Axor